Dr. Ahmad Al-Ghazawi
Dr. Ahmad Al-Ghazawi has over 29 years of experience inthe pharmaceutical sector. He has worked with Merckand Glaxo Smith Kline for over seven years as a pharmaceuticalscientist, later became the technical and development managerresponsible for directing, designing, and development of new andexisting Merck drug delivery systems ( DDS ).Prior to joining SmithKline he was a senior pharmaceutical scientist at NortonHealthcare for nearly 4 years and have been involved in designing and developing of a novel dry powder inhaler and breath operated inhaler that won Prince Charles’s Award for Innovation in UK,1996.
Dr. Al-Ghazawi is a member of the American Association of Pharmaceutical Scientist (AAPS); USA, the Controlled Release Society Inc.; USA, the Royal Pharmaceutical Society of Great Britain – Academy of Pharmaceutical Sciences and The Aerosol Society; UK. Dr Al-Ghazawi was a visiting lecturer teaching 2/3-year pharmaceutical chemistry students for 1998-1999 courses at the University of Kent, Canterbury, UK.
Dr. Al-Ghazawi is an inventor/co-inventor of many patents in drug delivery systems. One of his patents covers Paroxetine salt, an antidepressant drug. Paxil® (Paroxetine HCl) sells at $2.2 billion in the USA annually. Dr Al-Ghazawi received his PhD from the School of Pharmacy, University of London,-UK, B.Pharm., from Jordan University of Science and Technology- Jordan and his high school Diploma from the USA.